ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs
Dec 09, 2022
Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one of them.
The 64th ASH Annual Meeting and Exposition is a four-day premier event in malignant and non-malignant hematology, scheduled to start on December 10, 2022. Like every year, the ASH conference shared new abstracts from a robust portfolio and pipeline of advanced therapeutic platforms in cancer and other blood disorders, highlighting the impact of our bold science in research. On this note, Delveinsight has listed a few major abstracts for diffuse large B-cell lymphoma (DLBCL).
The key abstracts have been summarized in the table below:
Downloads
Article in PDF
Recent Articles
- Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Findings at ASH 2021
- Snippet: M&A activities of big pharma’s will fuel CAR-T cell therapy
- Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!
- Major Highlights of Follicular Lymphoma (FL) in ASH 2021
- New method for classification of CNS tumors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Downloads
Article in PDF
Recent Articles
- Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market
- US drug approvals plummet in 2016
- Business Cocktail
- Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Ma...
- Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial
